Murine models of renal disease: Possibilities and problems in studies using mutant mice by Anders, Hans-Joachim & Schlöndorff, Detlef
Editorial Review
Exp Nephrol 2000;8:181–193
Murine Models of Renal Disease:
Possibilities and Problems in Studies
Using Mutant Mice
Hans-Joachim Anders Detlef Schlöndorff
Medizinische Poliklinik der Ludwig-Maximilians-Universität, München, Deutschland
Received: February 24, 1999
Accepted: August 26, 1999
Dr. H.-J. Anders
Medizinische Poliklinik der Ludwig-Maximilians-Universität
Pettenkoferstrasse 8a, D–80336 München (Germany)
Tel. +49 89 51603565, Fax +49 89 51603420
E-Mail hjanders@clinbio.med.uni-muenchen.de
ABC
Fax + 41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com
© 2000 S. Karger AG, Basel
1018–7782/00/0085–0181$17.50/0
Accessible online at:
www.karger.com/journals/exn
Key Words
Renal disease W Glomerulonephritis W
Glomerulosclerosis W Interstitial nephritis W Backcrossing W
Renovascular hypertension W Transgenic mice
Abstract
The elucidation of the pathogenesis of human renal dis-
ease at the molecular level has been facilitated by the
growing field of gene targeting and the development of
mouse strains with single-gene deletions – the ‘knock-
out’ mice. Experimental nephrology, therefore, requires
well-characterized and reliable models of human renal
disease that can be induced reproducibly in mice. Today
surgical procedures for the induction of renal ischemia,
chronic renal failure, and ureter obstruction are feasible
in mice. Models of mesangioproliferative or crescentic
glomerulonephritis, glomerulosclerosis, and tubuloin-
terstitial disease are readily available; however, these
depend heavily on the mouse genetic background. At-
tention to the genetic background and appropriate back-
crossing are, therefore, of great importance in the design
and interpretation of experimental studies, especially in
transgenic mice. Simple murine models displaying the
clinical features of other human renal diseases such as
IgA nephropathy, membranous glomerulonephritis, and
renal vasculitis are still lacking. Mouse strains that spon-
taneously develop distinct renal pathologies similar to
lupus nephritis and focal-segmental glomerulosclerosis
can be intercrossed with transgenic mice to study the
impact of single-gene deletions on the renal phenotype.
The present review provides a survey about currently
available spontaneous and inducible murine models of
renal disease with special attention to problems and
future perspectives for their use in transgenic animals.
Copyright © 2000 S. Karger AG, Basel
Introduction
Most of the present knowledge on renal physiology and
pathophysiology is based on experimental work with labo-
ratory animals. Important therapeutic concepts in neph-
rology were developed in animal models of renal disease.
While rats have extensively been used for measuring renal
physiologic processes, by, e.g., micropuncture and clear-
ance studies, mice are usually preferred for immunologi-
cal studies in general [1]. Because of their small size, mice
are not as convenient as rats for surgical and micropunc-
ture studies. On the other hand, the availability of many
genetically defined strains and mouse-specific immuno-
logical reagents renders mice highly suitable for studies on
cellular and humoral immunology of renal diseases.
Inbred strains such as nude mice or severe combined
immunodeficient mice are available to study the func-
tional relevance of certain components of the immune
D
ow
nl
oa
de
d 
by
: 
UB
 d
er
 L
M
U 
M
ün
ch
en
   
   
   
   
   
   
   
   
   
   
   
   
 
12
9.
18
7.
25
4.
47
 - 
8/
12
/2
01
3 
12
:0
2:
20
 P
M
182 Exp Nephrol 2000;8:181–193 Anders/Schlöndorff
system in experimental renal disease [2]. Compared to
rats, there are many more mouse strains available with
spontaneously occurring disease models, such as lupus
nephritis, polycystic kidney disease, hypertension, inter-
stitial disease, or diabetes [3–5]. Furthermore, the recent
introduction of targeted gene disruption in embryonic
stem cells by homologous recombination allows the devel-
opment of mice with specific homozygous gene deletions,
the knockout (–/–) mice [6]. By this technology, the func-
tional role of distinct genes in the pathophysiology of dis-
ease can be studied [7]. Although most knockout mice
have a normal phenotype, certain gene deletions can be
lethal, depending on the function of the particular gene
during embryonal development [8, 9]. To study the rele-
vance of such molecules in the pathophysiology of dis-
ease, the insertion of substrate-responsive promoters and
cell type specific promoters allows the temporal control,
i.e., switch on or switch off of gene expression, known as
‘conditional gene targeting’ or even cell type specific gene
targeting [10]. The present and future technologies for
generating transgenic mice offer great possibilities for
studies on single or even multiple gene functions in dis-
tinct renal diseases. In order to exploit the transgene tech-
nology, reliable murine models of human renal disease are
of particular importance [11].
Experimental Disease in Transgenic Animals:
Problems and Future Perspectives
Understanding the molecular mechanisms of human
renal diseases by identifying key genes may help to estab-
lish gene-targeted therapy concepts as more specific thera-
peutic strategies in nephrology [12]. The development of
homozygous gene-deleted mutant mice offers great ad-
vantages for the functional study of single genes in the
pathophysiology of disease processes [13]. Thus structural
changes of chronic diseases can be elicited by overexpress-
ing or eliminating genes. However, the phenotype of
many disease models is rather strain specific and depends
on the genetically determined immune response after a
certain stimulus. Inbred laboratory mouse strains such as
C57BL/6 or Balb/c are, therefore, required. Unfortunate-
ly, the generation of transgenic mice requires the em-
bryonic stem (ES) cells of the 129 mouse strain with an
undefined genetic background. The problem of an unde-
fined genetic background in transgenes also includes the
lack of adequate controls. Because of marked polymor-
phism in the genetic background of many laboratory
mouse strains, it cannot be concluded that the null muta-
tion is the only cause for a phenotypical change [14]. This
problem is widely underappreciated, since in early back-
cross generations even hybrid littermate controls are ge-
netically different at the targeted gene locus and other
gene loci. Due to technical reasons, gene targeting is usual-
ly carried out in the 129 strain ES cells, an outbread
mouse strain. ES cell transfer into blastocystes of another
mouse strain results in chimeras, of which homozygous
individuals are further crossed with, e.g., C57BL/6 mice,
resulting in a mixed 129/C57 genotype. According to
Mendel’s law, crossing of two +/– mutants for the specific
gene generates F2 offspring of a 1 ! (+/+) – 2 ! (+/–) –
1 ! (–/–) genotype. Inbreeding of homozygous –/– and
+/+ F2 offspring results in two genetically different inbred
lines, one –/– and the other +/+, for the targeted gene.
However, the genetic background is completely different
due to inbreeding of two segregated genetically different
strains. Therefore, using such a crossing regimen does not
produce appropriate controls for null mutants. Instead,
simultaneous backcrossing into two congenic strains, i.e.,
129 strain of the ES cell and C57BL/6 of the blastocyte
origin, is necessary. F1 hybrids of these different back-
cross strains have a well-defined 50:50 genotype [15].
However, alleles of genes that closely surround the tar-
geted locus are derived from the ES cell origin and may
remain together with the mutated gene because the proba-
bility of genetic recombination relies on the distance
between the gene loci. This aspect may be important in
backcrossing null mutants of, e.g., immunoglobulin, cyto-
kine, or chemokine genes which appear in gene clusters.
Backcrossing or crossbreeding is also required for stud-
ies in particular strains with spontaneously occurring
renal disease or when disease susceptibility is restricted to
a specific strain. Starting from unrelated strains, a congen-
ic line is statistically expected to be 99.9% congenic after
ten generations of backcrossing, which may take as much
as 2 years of breeding time. After the fifth backcross gen-
eration, the contribution of additional backcrossing is
limited, so that the use of F5 congenic strain hybrids for
initial experiments has been suggested [15]. Clearly, the
large variations in, e.g., immunological responses between
different mouse strains pose a major problem with the
interpretation of experimental disease variations in trans-
genic mice when adequate backcrossing has not been per-
formed. This problem cannot be underestimated [16].
Establishing robust pluripotent C57BL/6 ES cell lines
would help to generate null mutants without genetic poly-
morphism, but unfortunately such ES cells are currently
not available. Today the most promising perspective is
the generation of transgenic animals with inducible ex-
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pression of targeted genes. Such conditional knockouts
also avoid the problem of compensatory mechanisms of
null mutants and can be cell or organ specific. The cre-lox
system uses bacteriophage-derived Cre recombinase to
catalyze site-specific recombination by crossing-over be-
tween two Cre recognition sequences (i.e., LoxP sites)
[17]. DNA sequences introduced between two LoxP sites
can be excised by Cre-related recombination. Controlling
Cre expression by insertion of a hormone-responsive pro-
moter construct allows temporal control of gene expres-
sion, known as ‘conditional gene targeting’ [10]. Generat-
ing such animals does not require wild-type controls, as
the phenotype can be analyzed before and after the condi-
tional gene targeting experiment as an internal control. In
transgenes, insertion of a stop codon between the promot-
er sequence and the targeted cDNA Cre-related recombi-
nation of the stop codon may also allow temporal switch-
ing off of gene overexpression [17]. Furthermore, recently
tissue- or cell-specific promoter constructs have been used
to generate conditional transgenic mice with a tissue-spe-
cific gene expression [18–20]. This may further overcome
the problem of distinguishing between systemic versus
local action of proteins, which is impossible by conven-
tional gene targeting. For example, inverse glucokinase
expression under the control of an intrinsic albumin or
insulin promoter resulted in severe postnatal diabetes
only in mice with pancreatic beta cell but not hepatocyte-
specific gene expression [21]. The impact of temporal and
cell-specific control of gene expression on studies of renal
physiology and disease has been reviewed recently [22].
As the genetic background is of such importance for
transgenic studies, reproducible models of renal disease
with a well-defined genetic background are essential. In
the following, we, therefore, provide a survey of sponta-
neous or inducible models of experimental renal disease
in mice. Procedures, susceptible mouse strains, and recent
experiences in studies using mutant mice are summa-
rized.
Glomerulonephritis
Immune Complex Glomerulonephritis due to
Exogenous Antigens
Human immune complex dependent glomerulopathies
include lupus nephritis, IgA nephropathy, postinfectious
and poststreptococcal glomerulonephritis, endocarditis,
shunt infection associated nephritis, and glomerulone-
phritis caused by other unknown antigens. The classic
example of experimental glomerulonephritis caused by
immune complexes is serum sickness, resulting from an
immune response against administered foreign antigens.
Repeated injections of the antigen maintain a slight circu-
lating antigen excess, causing immune complex deposi-
tion. However, since the immune response depends on
size, charge, and antigenicity of the antigen, only few het-
erologous proteins have been shown to reliably cause pro-
gressive proliferative glomerulonephritis in susceptible
mouse strains (table 1) [23–27].
Presensitization with antigen in adjuvant, as used by
most protocols, is not required for the apoferritin-induced
glomerulonephritis model [28]. The model is character-
ized by a mesangioproliferative and necrotizing glomeru-
lonephritis with leukocyte infiltration, tuft thrombosis,
and moderate proteinuria within 10–14 days and can pro-
gress to glomerulosclerosis [29]. Interstrain variations of
apoferritin susceptibility are not related to the major his-
tocompatibility complex, but depend on the production
of high-avidity antibodies [30–32]. The susceptibility of
Balb/c but not of C57BL/6 mice and the relation to anti-
body production indicates that the apoferritin model
depends on a Th-2-type immune response. Using apofer-
ritin-induced glomerulonephritis in C3-, C4-, and C5-
deficient mice, it was demonstrated that C3 and C5 are
critical mediators of immune complex glomerulonephri-
tis in vivo and that C4-deficient mice develop nephritis
by activating C3 via the alternative pathway irrespective
of glomerular IgG deposition [33, 34]. Apoferritin-in-
duced glomerulonephritis is, therefore, a reliable model of
mesangial proliferative immune complex glomerulone-
phritis in transgenes backcrossed into the Balb/c strain.
IgA nephropathy is the most common human glomeru-
lonephritis, and much effort has been put into estab-
lishing an animal model with mesangial IgA deposits,
hematuria, and proliferative glomerular lesions, unfortu-
nately with only limited success to date [35, 36]. In mice,
mesangial IgA deposits have been induced by different
oral antigens such as gliadin, ovalbumin, lactalbumin,
dextran, or ferritin or by experimental liver disease [37–
43]. These studies have focused on IgA immune complex
deposition, but proliferative glomerulonephritis has not
been observed. Montinaro et al. [44] have established a
passive model of IgA nephropathy with hematuria, pro-
teinuria, and severe diffuse mesangioproliferative glomer-
ulonephritis by sequential administration of murine my-
eloma derived IgA antiphosphorylcholine antibodies and
pneumococcal C polysaccharide antigen. However, due to
the complicated immune complex preparation proce-
dures, this model has not been used by other groups.
Therefore, today there is no accepted and simple model of
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Table 1. Models of GN in mice
Technique Susceptible strains Histopathology Protein-
uria
Refe-
rences
Horse spleen apoferritin 4 mg i.p. daily for 2 weeks B10, D2, NZB, Balb/c, Swiss mesangioproliferative
necrotizing GN
++ 29
BSA 0.5 mg s.c. on weeks 0, 2, and 4;
from week 6 0.1–0.5 mg i.p. daily
C3H/NB mesangioproliferative or
crescentic GN
+ 27
IgA GN
IgA anti-PC and PnC i.v. C57/BL6 mesangioproliferative GN ++ 44
Mesangioproliferative GN
Habu venom, 4 mg/kg C57BL/6N, BALB/c, GRS/A mesangioproliferative GN,
capillary cysts
++ 67
Lupus nephritis
Spontaneous polyclonality and lupuslike disease (NZBxNZW)F1, MRL-lpr/lpr all WHO classes of
lupus nephritis
+++ 69
Anti-GBM GN
Sheep antimouse GBM globulin i.v. C57/BL6, Balb/c crescentic GN +++ 48
Sheep IgG s.c.; after 10 days sheep antimouse
GBM globulin 10 mg i.v.
C57/BL6, Balb/c crescentic GN +++ 50
GN = Glomerulonephritis; BSA = bovine serum albumin; anti-PC = antiphosphorylcholine antibodies; PnC = pneumococcal C polysac-
charide; GBM = glomerular basement membrane.
IgA nephropathy available. This may relate to the recent
observation that specific alterations in the glycosylation
of IgA contribute to the development of human IgA
nephritis [45]. So far, these findings have not been taken
into consideration when trying to establish murine mod-
els of IgA nephropathy.
Nephrotoxic Serum Nephritis
Nephrotoxic serum (NTS) nephritis is a commonly
used model for antiglomerular basement membrane ne-
phritis (anti-GBM) or in situ immune complex glomerulo-
nephritis. The passive model using a single intravenous
injection of heterologous antiserum is currently preferred
in studies focusing on the immunology of glomerulone-
phritis [1, 46, 47]. NTS is classically raised in sheep or
rabbits against crude preparations of glomeruli or GBM
and contains polyclonal antibodies against multiple
GBM, tubular basement memebrane (TBM), and endo-
thelial, mesangial, and epithelial cell wall antigens [48].
The NTS nephritis model is characterized by two differ-
ent phases resembling different diseases. An early heterol-
ogous phase due to linear anti-GBM antibody deposition
in the glomerulus that resembles anti-GBM disease; a sub-
sequent autologous immune response against the planted
antibodies results in an in situ immune complex forma-
tion, i.e., that resembles, e.g., postinfectious glomerulone-
phritis [48]. The autologous phase of NTS nephritis can
progress to crescentic glomerulonephritis [49]. Preimmu-
nization with rabbit IgG in incomplete Freund’s adjuvant
3–5 days prior to administration of a subnephritic dose of
rabbit antimouse GBM antiserum results in an aug-
mented autologous phase with nephrotic-range protein-
uria and acceleration of proliferative glomerular lesions
within 2–4 days [50]. Histologically a glomerular infiltrate
and a mixed periglomerular infiltrate are found. The cell
type of the glomerular infiltrate varies among different
inbred mouse strains. Th1-prone C57BL/6 mice develop
glomerular accumulation of CD4-positive T cells and
macrophages, whereas neutrophils predominate in Th2-
prone Balb/c mice [51, 52]. Inducing NTS nephritis in
interleukin 4 deficient mice supported the concept of
crescent formation as a delayed-type hypersensitivity
(Th1) response, since interleukin 4 deficiency (one of the
essential mediators of Th2 responses) enhanced crescen-
tic glomerular injury, [53, 54]. NTS nephritis has also
been used in mice deficient in various mediators of the
endothelium-leukocyte interaction. Glomerular leukocyte
infiltration was decreased in mice deficient in intercellu-
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lar adhesion molecule 1, C3, and C4, indicating the key
role of these factors during development of the leukocytic
infiltrate in this model [55, 56]. However, in mice defi-
cient in monocyte chemoattractant chemokine 1, tubular
injury but not glomerular damage was reduced, which
suggested a differential regulation of inflammation in kid-
ney compartments [57]. Glomerular damage remained
also unchanged in NOS-2 and mu chain deficient mice,
illustrating that these factors do not play an essential role
in this model of glomerulonephritis [58, 59]. It should be
pointed out, however, that some of these studies were per-
formed in knockout mice with insufficient backcrossing,
so that conclusions may not yet be firm.
Due to the progression of NTS nephritis to crescentic
glomerulonephritis during the autologous phase, this
model is useful for studies of renal fibrogenesis. The role
of various factors during renal fibrogenesis could be dem-
onstrated by a diminished crescent formation and renal
fibrosis after injection of NTS in mice deficient in either
tumor necrosis factor alpha, angiotensin II, major histo-
compatibility complex class II, CD4, or CD8 [60–63].
These studies showed that renal fibrosis secondary to glo-
merular inflammation depends on several paracrine-
secreted peptides and on cell surface receptors on intrinsic
renal cells or infiltrating leukocytes.
In summary, the NTS model represents a well-estab-
lished model of anti-GBM disease during the heterolo-
gous phase and of crescentic immune complex glomerulo-
nephritis during the autologous phase. The variant course
in Th1- and Th2-prone mouse strains allows studies of the
heterologous phase in the more humoral or cellular im-
mune responses of the different genetic backgrounds.
However, careful backcrossing of transgenes into the spe-
cific mouse strains is essential. Reliable development of
crescentic glomerulonephritis during the autologous
phase of NTS nephritis makes this model useful for stud-
ies of renal fibrogenesis and progressive renal failure.
However, due to the various antisera used, the two phases
of the model, and important strain differences, results of
different studies using NTS nephritis cannot readily be
compared to each other.
Mesangioproliferative glomerulonephritis can be in-
duced in rats and mice by a single intravenous injection of
4 mg/kg of Habu snake venom (Trimeresurus flavoviri-
dis). The model is similar to the anti-Thy-1 nephritis in
rats [64]. Within 3 days mesangiolysis is followed by glo-
merular cyst formation, and focal mesangioproliferative
lesions can be observed [65]. Histopathological abnormal-
ities include focal mesangial hypercellularity and nodular
mesangial lesions [64]. This model is particularly useful to
study mesangial proliferation independent of leukocyte
infiltration. At least in rats the initial phase of Habu snake
venom toxicity relies on platelet-dependent endothelial
damage which can be suppressed by antiplatelet agents,
whereas in mice the resolution of the proliferative lesions
depends on the cell-intercellular matrix interaction [66,
67].
Lupus Nephritis
Mouse strains with spontaneous polyclonal B cell acti-
vation, such as Fas-deficient MRL-lpr/lpr mice or New
Zealand black/white F1 hybrids, develop renal changes
comparable to those found in human lupus nephritis [23,
68–70]. Lupus nephritis is considered to have a multigen-
etic susceptibility. Therefore, susceptibility genes in spe-
cific mouse strains favor the development of a phenotype
which develops lupus nephritis after an unknown trigger-
ing event [71]. Murine systemic lupus erythematosus
strains have, therefore, been used to study the polygenetic
basis of the susceptibility to lupus nephritis [72]. In sys-
temic lupus erythematosus, circulating immune com-
plexes deposit in the glomerular subendothelial space and
in the mesangium, leading to glomerulonephritis. The
development of glomerular lesions involves multiple ad-
hesion molecules, cytokines, chemokines, lipid media-
tors, and Fc receptors [71]. Recently, crossbreeding Fc
gamma receptor deficient mutants with NZB/NZW hy-
brids resulted in mutant mice which showed glomerular
immune complexes and complement deposits, but did not
develop severe nephritis [73, 74]. These studies have been
interpreted to indicate a role for IgG receptors in the
development of immune complex glomerulonephritis.
Nephritis was also prevented in interferon gamma recep-
tor deficient MRL mice [75]. Crossbreeding of mice defi-
cient in intercellular adhesion molecule 1 with MRL mice
abrogated pulmonary inflammation, but not spontaneous
glomerulonephritis [76]. These studies illustrate the strat-
egy of combining transgenic mice with mutants carrying
spontaneous renal disease. Attempts to induce systemic
lupus erythematosus in mice without a specific genetic
background failed to establish a model mimicking human
lupus nephritis, again indicating the importance of genet-
ic susceptibility.
Glomerulosclerosis
Glomerulosclerosis is part of the final stage of many
immunologic and nonimmunologic glomerular disorders
[77]. The current pathogenic concepts of diffuse glomeru-
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Table 2. Models of diabetic nephropathy and glomerulosclerosis in mice
Technique Susceptible strains Histopathology Refe-
rences
Uninephrectomy, streptozotocin i.p.
for 5 days 1 week later
CD-1, others? mesangial expansion, GBM thickening,
glomerulosclerosis
96
Hyperinsulinemic diabetic mice db/db, KKay, NZO GBM thickening, diffuse glomerulosclerosis 100, 101
Hypoinsulinemic diabetic mice NOD GBM thickening, diffuse glomerulosclerosis 98
Glomerulosclerosis
4! lymphocytes from DBA/2 mice in
3- to 4-day intervals i.v., 10 weeks
(C57B1/10 ! DBA/2) F1 hybrids diffuse glomerulosclerosis 92
GH transgenic mice MThGH transgene, NMRI progressive glomerulosclerosis 81
Oligosyndactyly (Os) mouse Os/+ ROP 50% nephron number, glomerulosclerosis 88
Others SV40Tag, Thy-1, Mpv17/Mpv17 diffuse glomerulosclerosis 85, 86, 87
GH = Growth hormone; MThGH = metallothionein I promoter human growth hormone; GBM = glomerular basement membrane.
losclerosis include genetic susceptibility, glomerular hy-
pertrophy, podocyte damage, and glomerular hyperfiltra-
tion [78–80]. Commonly used mouse strains which spon-
taneously develop glomerulosclerosis are listed in table 2.
A well-characterized murine model of spontaneous
glomerulosclerosis is the growth hormone overexpressing
transgenic mouse [81–84]. Mice develop growth hormone
related glomerular hypertrophy with an increase of extra-
cellular mesangial matrix, resulting in focal-segmental
glomerulosclerosis between 7 and 9 weeks of age [84]. Pro-
gression to end-stage renal failure is characterized by
increasing nephrotic-range proteinuria, diffuse glomeru-
losclerosis, tubular atrophy, and interstitial fibrosis. Oth-
er transgenic mouse strains that spontaneously develop
glomerulosclerosis (if not kept in a germ-free environ-
ment) include Thy-1, SV40Tag, and Mpv17/Mpv17
transgenic mice [85–87]. The mechanisms and genes
involved in this process are not known. These observa-
tions also illustrate the importance of keeping all trans-
genes and their controls in a specific pathogen free animal
facility [85–87].
Another strain of mice with spontaneous development
of glomerulosclerosis is the oligosyndactyly (Os) mouse
[88]. Heterozygous animals of a ROP and a C57 back-
ground are born with a 50% reduction in the number of
nephrons associated with an increased glomerular volume
of the remaining nephrons [89]. The fact that an increase
of the mesangial matrix and glomerulosclerosis did only
occur in the ROP background argues for an inherited sus-
ceptibility to glomerulosclerosis [90].
Glomerulosclerosis may also occur late in the course of
immune system mediated glomerulopathies [91, 92]. One
group [29] has reported that 85% of their Balb/c mice
developed diffuse glomerulosclerosis 4 months after an
initial 2-week immunization with apoferritin, but this
observation needs to be confirmed.
Diabetic Nephropathy
Diabetic nephropathy is the most common cause of
glomerulosclerosis in humans [79]. Animal models of dia-
betes have used the beta cell toxin streptozotocin to relia-
bly induce insulin-dependent diabetes mellitus in various
rodents including mice (table 2) [93–95]. Uninephrecto-
my before induction of diabetes can shorten the interval
until typical glomerular abnormalities occur [96]. Fur-
thermore, several mouse strains that spontaneously devel-
op diabetes mellitus have been established [97]. Amongst
those the hypoinsulinemic nonobese diabetic mouse and
hyperinsulinemic ob/ob and KKAy mice develop only
minimal renal abnormalities [98–100]. The hyperinsu-
linemic diabetes mouse (C57BL/6 db/db) develops pro-
gressive renal disease characterized by kidney enlarge-
ment, hyperfiltration, and progressive proteinuria during
an early age [101]. Histopathological changes include dif-
fuse and nodular thickening of the mesangial matrix, exu-
dative lesions, and nodular thickening of he GBM [102,
103]. Similar lesions have also been found in polygeneti-
cally inherited diabetes of hyperinsulinemic New Zealand
obese mice [104]. Crossing of nonobese diabetic mice
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Table 3. Models of tubulointerstitial nephritis in mice
Technique Susceptible strains Histopathology Protein-
uria
Refe-
rences
SJL, CD1, A.CA, A.SW,
T.TL, Balb/c, NZB
tubular necrosis, lymphocyte infiltrate + 107
Unilateral ureter ligation any tubular atrophy, mixed infiltrate + 2
TBM = Tubular basement membrane; CFA = complete Freund’s adjuvant.
with ß2-microglobulin-deficient transgenes resulted in
mice with a lack of CD8+ T cells [105]. As compared with
diabetic controls, hybrids did not develop lymphocytic
insulitis, which illustrates that CD8+ T cells play an essen-
tial role in the development of diabetes in nonobese dia-
betic mice. However, intercrossing with diabetic mice is
difficult, especially in hypoinsulinemic mice. So far, the
impact of single gene deletions on the renal pathology of
diabetic mice has not been studied.
Tubulointerstitial Nephritis and Obstructive
Nephropathy
Human tubulointerstitial nephritis with interstitial in-
filtrate, tubular atrophy, and interstitial fibrosis can be
caused by drugs, toxins, infection, systemic immune dis-
ease, or obstructive nephropathy [106]. The mechanisms
of immunological tubulointerstitial injury have been as-
signed to immune complex formation with planted ne-
phritogenic antigens or with locally generated tubulointer-
stitial antigens and to cell-mediated immune mechanisms
[107]. Combinations of these with toxic or ischemic inju-
ry may be common. Mouse strains that spontaneously
develop interstitial nephritis and experimental ap-
proaches to interstitial nephropathy in mice are listed in
table 3.
A natural mutant that spontaneously develops tubu-
lointerstitial nephritis is the kdkd mouse [108]. A mixed
interstitial infiltrate followed by tubular atrophy and
interstitial fibrosis develops after 8 weeks of life. The dis-
ease can be transferred by L3T4 lymph node T cells into
cyclophosphamide-pretreated recipients of another in-
bred strain, which indicates the role of tubular antigen-
reactive T lymphocytes in the development of interstitial
nephritis in kdkd mice [109]. However, crossbreeding of
mice bearing transgenes with kdkd mice as a model of
tubulointerstitial disease has not been performed.
Murine anti-TBM interstitial nephritis is induced by a
single immunization with rabbit TBM [107]. Anti-TBM
antibodies are detectable after 2 weeks, but lesions of the
tubulointerstitial tissue do not occur before 9–16 weeks.
The SJL mouse strain is the most susceptible, but A.CA,
A.SW, T.TL, and NZB mice are also responding [110].
The susceptibility of mouse strains is related to the major
histocompatibility complex class II H-2-phenotypic trait
signalling T effector cells by proximal tubular cells [111,
112]. T lymphocyte transfer studies have also proven the
relevance of T cell autoimmunity in maintaining the
chronic phase of this model [113]. As compared with NTS
nephritis, anti-TBM nephritis is characterized by a long
delay until typical lesions appear. Furthermore, the dis-
ease has not been characterized in inbred mouse strains.
So far, anti-TBM interstitial nephritis has not been used
in null mutants.
A murine model that predictably and uniformly in-
duces tubulointerstitial damage independent of the genet-
ic background is unilateral ureter obstruction (UUO)
[114]. In adult mice the ureter is ligated supravesically by
an anterior approach using the contralateral kidney as a
control. 1–2 weeks after surgery a periglomerular and
interstitial infiltrate composed predominantly of macro-
phages and T lymphocytes develops [2]. Persistent UUO
results in progressive tubulointerstitial and periglomeru-
lar inflammation and fibrosis similar to what is found in
human obstructive nephropathy [115]. Amelioration of
interstitial collagen deposition after UUO was noted in
angiotensinogen, transforming growth factor, and CCR2
deficient mice, indicating that many growth factors, cyto-
kines, and chemokines are involved in the process of
interstitial inflammation and renal fibrogenesis [116–
118]. Since angiotensin type 2 receptor null mutant mice
and B7 transgenes developed an accelerated interstitial
fibrosis after UUO, these molecules seem to be important
regulators of fibrogenesis in obstructive nephropathy
[119, 120]. The ureter ligation model represents a repro-
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Table 4. Models of acute tubular necrosis in mice
Technique Susceptible strains Histopathology Protein-
uria
Refe-
rences
Renal artery clamping for 30 min,
reperfusion for 1–3 days
any tubular necrosis + 122
Toxic tubular necrosis
Folic acid 200 mg/kg in 0.3 M NaHCO3 i.p. CD1, C57BL/6, Balb/c, DBA/2 tubular necrosis ++ 129
Mercury chloride 100 Ìmol/kg i.v. C3H/He, 129/Sv, CBA/Bom tubular necrosis ++ 141
Cadmium 0.2 mg/kg i.v. or i.p. C3H/HeJ, CBA/CA, C57/BL10, DBA/2J tubular necrosis ++ 137
King brown snake myotoxin 4.5 mg/kg i.m. Swiss albino myolysis, myoglobin cast
nephropathy
++ 135
ducible model of interstitial inflammation and fibrosis
secondary to a nonimmune stimulus. The procedure is
easily performed, and the time course for progression to
renal fibrosis is short. Although the course may differ
between various mouse strains, the model itself can be
used in all strains. However, due to ureter ligation, pro-
teinuria cannot be used as a functional parameter of renal
damage in this model.
Acute Renal Failure
Ischemic Acute Renal Failure
Ischemia or hypoperfusion accounts for 50% of acute
renal failures in humans [121]. The reperfusion following
hypoperfusion has been implicated in the pathogenesis of
tissue damage. Studies on the mechanisms of reperfusion
injury in acute renal failure have used renal artery clamp-
ing for transient interruption of renal perfusion in mice
(table 4) [122]. One kidney is exposed by flank incision,
and the renal artery is clamped with a nontraumatic vas-
cular clamp for 30 min using the contralateral kidney as a
control [123]. Although immediate-early genes in renal
tissue are already activated after 10 min of arterial occlu-
sion, significant tubular injury related azotemia has only
been found after 30 min of clamping and subsequent
reperfusion during the next 24–72 h [124, 125]. Using this
protocol, the relevance of adhesion molecules in the
pathogenesis of ischemic nephropathy was studied. Inter-
cellular adhesion molecule 1 deficient mice were pro-
tected from acute renal ischemic injury, whereas L-se-
lectin-deficient mutants had an unchanged response as
compared with wild-type controls [126–128]. However,
interpretation of renal artery clamping data must consider
the uncertainties of this model. Ischemia-related renal
injury may vary from animal to animal due to technical
problems such as surgery, blood loss, maintenance of
body temperature during anesthesia, length of operation,
and arterial hypotension during the postoperative period
which is influenced by the anesthetics and analgesics
used. As in humans, the surgical skill of the experimenta-
tor has considerable influence on the outcome even when
a standardized ‘ischemia’ time is used.
Toxic Tubular Necrosis
Nephrotoxins that reliably induce acute tubular necro-
sis in mice include folic acid, cadmium, mercury, and
king brown snake venom as listed in table 4. Depending
on the dose administered, either a temporary decrease of
renal function or lethal uremia occurs.
A single intraperitoneal injection of folic acid in sodi-
um bicarbonate induces acute renal failure and compen-
satory hypertrophy between days 1 and 4 in mice of most
strains [129, 130]. Degree and reversibility of acute renal
failure are related to the dose administered. Because of
the good reproducibility of folic acid induced tubular
necrosis, this model has been commonly used for studies
of differential gene expression after acute renal injury
[131, 132].
Trauma-related myoglobinuria is a common cause of
acute tubular necrosis [133]. Ponraj and Gopalakrishna-
kone [134] have developed a murine model of myoglobin
cast nephropathy by injecting 4.5 mg/kg of king brown
snake venom (Pseudechis australis) which causes rhabdo-
myolysis (table 4). Experimental mice develop myoglo-
binuria 60 min after administration of the myotoxic ven-
om. Myocyte necrosis and macrophage infiltration were
observed as early as 30 min, with the peak of infiltration
D
ow
nl
oa
de
d 
by
: 
UB
 d
er
 L
M
U 
M
ün
ch
en
   
   
   
   
   
   
   
   
   
   
   
   
 
12
9.
18
7.
25
4.
47
 - 
8/
12
/2
01
3 
12
:0
2:
20
 P
M
Electrocoagulation of the anterior surface of the
Murine Models of Renal Disease Exp Nephrol 2000;8:181–193 189
Table 5. Models of chronic renal failure (remnant-kidney models) in mice
Technique Mortality, % Characteristics References
right kidney, left-sided nephrectomy after 2–3 weeks
4–15 growth retardation, anemia, azotemia, osteodystrophy,
polyuria, proteinuria
146
Diathermy of the anterior surface and ligation
of the upper and lower poles of the right kidney,
left-sided nephrectomy after 2 weeks
20–50 growth retardation, anemia, azotemia, osteodystrophy,
altered immunological status
144, 145
Diathermy of the left kidney anterior surface,
right-sided nephrectomy after 1 week
20 growth retardation, azotemia 143
after 12–48 h [135]. Histopathological changes of the kid-
ney include intratubular myoglobin casts and tubular
necrosis. Thus snake venom related rhabdomyolysis pro-
vides an excellent murine model for acute myoglobinuric
renal failure.
Acute exposure to inorganic cadmium causes hepato-
toxicity, but no renal injury [136]. In contrast, during
chronic exposure cadmium is bound to metallothionein
by the liver, and this compound is filtered and accumu-
lates in renal tubular cells where it induces nephrotoxicity
[137]. In mice, a single injection of 0.2 mg/kg cadmium
bound to metallothionein can produce nephrotoxicity
similar to that seen with chronic cadmium exposure
[138]. Acute tubular dysfunction is characterized by
marked proteinuria from day 1 to 5 after cadmium-metal-
lothionein injection and by increasing levels of aminoac-
iduria and glucosuria with a peak on day 6 [137].
Environmental exposure to mercury compounds is an
important cause of heavy metal induced renal toxicity
in humans [139, 140]. In mice, injection of 100 Ìmol/kg
methylmercury chloride produces acute proximal tubular
necrosis after 2–3 days, followed by regeneration between
days 3 and 7 [141]. Strain and sex differences of renal tox-
icity rely on the distribution of apical Á-glutamyltranspep-
tidase in the proximal tubule which catalyzes transport of
the mercury-glutathione complex [142]. All models are
reproducible and can be induced by a single intraperito-
neal injection which makes them suitable for studies of
toxic tubular necrosis.
Chronic Renal Failure (Remnant-Kidney Models)
End-stage renal disease in mice can be induced by sur-
gical reduction of the renal mass. By progressive reduc-
tion of the renal mass, various degrees of renal failure with
the typical clinical, hematological, and biochemical fea-
tures of uremia can be induced [143–146] (table 5). Care-
ful ablation of the renal mass in a two-time procedure
improves perioperative mortality, as listed in table 5
[143]. For the evaluation of progressive deterioration of
renal function, mice have to be monitored carefully. In
mice the serum creatinine levels do not parallel the glo-
merular filtration rate because of low muscle mass and
tubular creatinine secretion, but the blood urea nitrogen
concentration can be used instead [147, 148]. However,
due to the ablation of renal mass, the amount of renal tis-
sue that can be obtained for histological studies or RNA
preparation is limited. The remnant-kidney model has,
therefore, been used to study the humoral changes in ure-
mia. The impaired host defense mechanisms observed in
this model have been used to study uremia-related immu-
nosuppression [149]. Other similarities to human disease
such as the reversibility of anemia by recombinant eryth-
ropoietin underline the suitability of this model for stud-
ies of end-stage renal failure [150].
Concluding Remarks
Reliable murine models resembling many human renal
disorders have been established for chronic renal failure,
immune complex glomerulonephritis, lupus nephritis, tu-
bulointerstitial nephritis, obstructive nephropathy, and
diabetic nephropathy. Murine models displaying the clin-
ical features of human disease are still lacking for such
important disorders as IgA nephropathy, membranous
glomerulonephritis, and renal vasculitis. Experimental re-
nal diseases in mice are important because of the expand-
ing field of gene targeting, molecular nephrology, and
gene therapy. Differences in the response to injury and the
immune response in different genetic mouse strains repre-
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sent a major problem in interpreting results obtained with
transgenic mice. Backcrossing into two congenic strains
for at least five generations is neccessary to obtain hybrids
where wild-type and knockout littermates can reliably be
compared. For several inducible models of renal disease,
transgenes must be backcrossed into distinct susceptible
inbred strains. The development of conditional transgen-
ic mice with tissue- or cell-specific gene expression or sup-
pression will be of particular importance in the future
study of molecular mechanisms of renal disease.
References
1 Salant DJ, Cybulsky AV: Experimental glomer-
ulonephritis. Methods Enzymol 1988;162:
421–461.
2 Shapell SB, Gurpinar T, Lechago J, Suk WN,
Truong LD: Chronic obstructive uropathy in
severe combined immunodeficient (SCID)
mice: Lymphocyte infiltration is not required
for progressive tubulointerstitial injury. J Am
Soc Nephrol 1998;9:1008–1017.
3 Robinson RR, Dennis VW: Spontaneously oc-
curring animal models of human kidney dis-
eases and altered renal function. Adv Nephrol
Necker Hosp 1980;9:315–366.
4 Schieren G, Pey R, Bach J, Hafner M, Gretz N:
Murine models of polycystic kidney disease.
Nephrol Dial Transplant 1996;11(suppl 6);38–
45.
5 Velasquez MT, Kimmel PL, Michaelis OE 4th:
Animal models of spontaneous diabetic kidney
disease. FASEB J 1990;4:2850–2859.
6 Majzoub JA, Muglia LJ: Knockout mice. N
Engl J Med 1996;34:904–907.
7 Wang T, Giebisch G: Tubule function in trans-
genic mice. Exp Nephrol 1998;6:447–453.
8 Raabe M, Flynn LM, Zlot CH, Wong JS, Ve-
niant MM, Hamilton RL, Young SG: Knock-
out of the abetalipoproteinemia gene in mice:
Reduced lipoprotein secretion in heterozygotes
and embryonic lethality in homozygotes. Proc
Natl Acad Sci USA 1998;95:8686–8691.
9 Farese RV Jr, Ruland SL, Flynn LM, Stokow-
ski RP, Young SG: Knockout of the mouse
apolipoprotein B gene results in embryonic
lethality in homozygotes and protection against
diet-induced hypercholesterolemia in heterozy-
gotes. Proc Natl Acad Sci USA 1995;28:1774–
1778.
10 Rajewsky K, Gu H, Kuhn R, Betz UA, Muller
W, Roes J, Schwenk F: Conditional gene target-
ing. J Clin Invest 1996;98:600–603.
11 Ryffel B: Gene knockout mice as investigative
tools in pathophysiology. Int J Exp Pathol
1996;77:125–141.
12 Kitamura M: Transfer of genetically engi-
neered cells to the glomerulus. Exp Nephrol
1997;7:259–266.
13 Lakkis FG: Role of cytokines in tansplantation
tolerance: Lessons learned from gene-knockout
mice. J Am Soc Nephrol 1998;9:2361–2367.
14 Lathe R: Mice, gene targeting, and behaviour:
More than just genetic background. Trends
Neurosci 1996;19:183–186.
15 Banbury Conference on Genetic Background
in Mice: Mutant mice and neuroscience:
Recommendations concerning genetic back-
ground. Neuron 1997;19:755–759.
16 Gerlai R: Gene-targeting studies of mammali-
an behavior: Is it the mutation or the back-
ground genotype? Trends Neurosci 1996;19:
177–181.
17 Furth PA, St Onge L, Boger H, Gruss P, Gossen
M, Kistner A, Bujard H, Henninghausen L:
Temporal control of gene expression in trans-
genic mice by a tetracycline-responsive pro-
moter. Proc Natl Acad Sci USA 1994;91:9302–
9306.
18 Lakso M, Sauer B, Mosinger B Jr: Targeted
oncogene activation by site-specific recombi-
nation in transgenic mice. Proc Natl Acad Sci
USA 1992;89:6232–6236.
19 Gu H, Marth JD, Orban PC, Mossmann H,
Rajewsky K: Deletion of a DNA polymerase
beta gene segment in T cells using cell type-spe-
cific gene targeting. Science 1994;265:103–
106.
20 Schwenk F, Kuhn R, Angrand PO, Rajewsky
K, Stewart AF: Temporally and spatially regu-
lated somatic mutagenesis in mice. Nucleic
Acids Res 1998;26:1427–1432.
21 Postic C, Shiota M, Niswender KD, Jetton TL,
Chen Y, Moates JM, Shelton KD, Lindner J,
Cherrington AD, Magnuson MA: Dual roles
for glucokinase in glucose homeostasis as deter-
mined by liver and pancreatic beta cell-specific
gene knock-outs using Cre recombinase. J Biol
Chem 1999;274:305–315.
22 Jaisser F, Beggah AT: Transgenic models in
renal tubular physiology. Exp Nephrol 1998;6:
438–446.
23 Furness PN, Harris K: An evaluation of experi-
mental models of glomerulonephritis. Int J Exp
Pathol 1994;75:9–22.
24 Noble B, Brentjens JR: Experimental serum
sickness. Methods Enzymol 1988;162:484–
901.
25 Furness PN: The formation and fate of glomer-
ular immune complex deposits. J Pathol 1991;
164:195–202.
26 Germuth FG, Rodriguez E, Lorelle CA, Trump
EI, Milano L, Wise O: Passive immune com-
plex glomerulonephritis in mice: Models for
various lesions found in human diseases. I.
High avidity complexes and mesangiopathic
glomerulonephritis. Lab Invest 1979;41:360–
365.
27 Noble B, Olson KA, Milgrom M, Albini B: Tis-
sue deposition of immune complexes in mice
receiving daily injections of bovine serum albu-
min. Clin Exp Immunol 1980;42:255–262.
28 Hagstrom GL, Bloom BM, Yum MN, Lavelle
KJ, Luft FC: Ferritin- and apoferritin-induced
immune complex glomerulonephritis in mice.
Nephron 1979;24:127–133.
29 Iskandar SS, Gifford DR, Emancipator SN:
Immune complex acute necrotizing glomerulo-
nephritis with progression to diffuse glomeru-
losclerosis: A murine model. Lab Invest 1988;
59:772–779.
30 Iskandar SS, Jennette JC, Wilkman AS, Becker
RL: Interstrain variations in nephritogenicity
of heterologous protein in mice. Lab Invest
1982;46:344–351.
31 Iskandar SS, Jennette JC: Influence of antibody
avidity on glomerular immune complex local-
ization. Am J Pathol 1983;112:155–159.
32 Iskandar SS, Jennette JC: Interaction of anti-
gen load and antibody response in determin-
ing heterologous protein nephritogenicity in
inbred mice. Lab Invest 1983;48:726–734.
33 Falk RJ, Jennette JC: Immune complex in-
duced glomerular lesions in C5 sufficient and
deficient mice. Kidney Int 1986;30:678–686.
34 Quigg RJ, Lim A, Haas M, Alexander JJ, He C,
Carroll MC: Immune complex glomerulone-
phritis in C4- and C3-deficient mice. Kidney
Int 1998;53:320–330.
35 Galla JH: IgA nepropathy. Kidney Int 1995;47:
377–387.
36 Rifai A: Experimental models of IgA-associat-
ed nephritis. Kidney Int 1987;31:1–7.
37 Coppo R, Mazzucco G, Martina G, Rocatello
D, Amore A, Novara R, Bargoni A, Piccoli G,
Sena LM: Gluten-induced experimental IgA
glomerulopathy. Lab Invest 1989;60:499–506.
38 Emancipator SN, Gallo GR, Lamm ME: Ex-
perimental IgA nephropathy induced by oral
immunization. J Exp Med 1983;157:572–582.
39 Emancipator SN, Gallo GR, Razaboni R,
Lamm ME: Experimental cholestasis promotes
the deposition of glomerular IgA immune com-
plexes. Am J Pathol 1983;113:19–26.
40 Gonzales E, Gonzales-Cabrero J, Egido J: De-
fective hepatic handling of IgA immune aggre-
gates by mice with experimental IgA nephropa-
thy. Immunology 1989;67:303–313.
41 Sato M, Ideura T, Koshikawa S: Experimental
IgA nephropathy in mice. Lab Invest 1986;54:
377–384.
42 Isaacs KL, Miller F: Role of antigen size and
charge in immune complex glomerulonephri-
tis. I. Active induction of disease with dextran
and its derivates. Lab Invest 1982;47:198–
205.
D
ow
nl
oa
de
d 
by
: 
UB
 d
er
 L
M
U 
M
ün
ch
en
   
   
   
   
   
   
   
   
   
   
   
   
 
12
9.
18
7.
25
4.
47
 - 
8/
12
/2
01
3 
12
:0
2:
20
 P
M
Murine Models of Renal Disease Exp Nephrol 2000;8:181–193 191
43 Isaacs KL, Miller F: Antigen size and charge in
immune complex glomerulonephritis. II. Pas-
sive induction of immune deposits with dex-
tran-anti-dextran immune complexes. Am J
Pathol 1983;111:298–306.
44 Montinaro V, Aventaggiato L, Cavallo T, Rifai
A: Evolution of renal injury in a chronic model
of IgA immune-complex-associated nephropa-
thy. Nephrol Dial Transplant 1995;10:2035–
2042.
45 Feehally J, Allen AC: Structural features of IgA
molecules which contribute to IgA nephropa-
thy. J Nephrol 1999;12:59–65.
46 Assmann KJ, Tangelder MM, Lange WP,
Schrijver G, Koene RA: Anti-GBM nephritis
in the mouse: Severe proteinuria in the heterol-
ogous phase. Virchows Arch A Pathol Anat
Histopathol 1985;406:285–299.
47 Wilson CB: Immune models of glomerular in-
jury; in Neilson EG, Couser WC (eds): Immu-
nologic Renal Diseases. New York, Lippincott-
Raven, 1997, pp 729–774.
48 Schrijver G, Bogman MJ, Assmann KJ, de
Waal RM, Robben HJ, van Gasteren H, Koene
RA: Anti-GBM nephritis in the mouse: Role of
granulocytes in the heterologous phase. Kidney
Int 1990;38:86–95.
49 Bolton WK, Benton FR, Sturgill BC: Autoim-
mune glomerulotubular nephropathy in mice.
Clin Exp Immunol 1978;33:463–473.
50 Tipping PG, Huang XR, Berndt MC, Holds-
worth SR: A role for P-selectin in complement-
independent neutrophil-mediated glomerular
injury. Kidney Int 1994;46:79–88.
51 Huang XR, Tipping PG, Shuo Li, Holdsworth
S: Th1 responsiveness to nephritogenic anti-
gens determines susceptibility to crescentic glo-
merulonephritis in mice. Kidney Int 1997;51:
94–103.
52 Huang XR, Holdsworth SR, Tipping PG: Th-2
responses induce humorally mediated injury in
experimental anti-glomerular basement mem-
brane glomerulonephritis. J Am Soc Nephrol
1997;8:1101–1108.
53 Kitching AR, Holdsworth SR, Tipping PG:
IFN-gamma mediates crescent formation and
cell-mediated immune injury in murine glo-
merulonephritis. J Am Soc Nephrol 1999;10:
752–759.
54 Kitching AR, Tipping PG, Mutch DA, Huang
XR, Holdsworth SR: Interleukin-4 deficiency
enhances Th1 responses and crescentic glomer-
ulonephritis in mice. Kidney Int 1998;53:112–
118.
55 Janssen U, Ostendorf T, Gaertner S, Eitner F,
Hedrich HJ, Assmann KJ, Floege J: Improved
survival and amelioration of nephrotoxic ne-
phritis in intercellular adhesion molecule-1
knockout mice. J Am Soc Nephrol 1998;9:
1805–1814.
56 Sheerin NS, Springall T, Carroll MC, Hartley
B, Sacks SH: Protection against anti-glomeru-
lar basement membrane (GBM)-mediated ne-
phritis in C3- and C4-deficient mice. Clin Exp
Immunol 1997;110:403–409.
57 Tesch GH, Schwarting A, Kinoshita K, Lan
HY, Rollins BJ, Kelley VR: Monocyte che-
moattractant protein-1 promotes macrophage-
mediated tubular injury, but not glomerular
injury, in nephrotoxic serum nephritis. J Clin
Invest 1999;103:73–80.
58 Cattell V, Cook HT, Ebrahim H, Waddington
SN, Wei XQ, Assmann KJ, Liew FY: Anti-
GBM glomerulonephritis in mice lacking nitric
oxide synthase type 2. Kidney Int 1998;53:
932–936.
59 Li S, Holdsworth SR, Tipping PG: Antibody
independent crescentic glomerulonephritis in
mu chain deficient mice. Kidney Int 1997;51:
672–678.
60 Li S, Kurts C, Kontgen F, Holdsworth SR, Tip-
ping PG: Major histocompatibility complex
class II expression by intrinsic renal cells is
required for crescentic glomerulonephritis. J
Exp Med 1998;188:597–602.
61 Hisada Y, Sugaya T, Yamanouchi M, Uchida
H, Fujimura H, Sakurai H, Fukamizu A, Mara-
kami K: Angiotensin II plays a pathogenic role
in immune-mediated renal injury in mice. J
Clin Invest 1999;103:627–635.
62 Ryffel B, Eugster H, Haas C, Le Hir M: Failure
to induce anti-glomerular basement membrane
glomerulonephritis in TNF alpha/beta defi-
cient mice. Int J Exp Pathol 1998;79:453–460.
63 Tipping PG, Huang XR, Qi M, Van GY, Tang
WW: Crescentic glomerulonephritis in CD4-
and CD8-deficient mice: Requirement for
CD4 but not CD8 cells. Am J Pathol 1998;152:
1541–1548.
64 Eitner F, Westerhuis R, Burg M, Weinhold B,
Grone HJ, Ostendorf T, Ruther U, Koch KM,
Rees AJ, Floege J: Role of interleukin-6 in
mediating mesangial cell proliferation and ma-
trix production in vivo. Kidney Int 1997;51:
69–78.
65 Cattell V, Bradfield JW: Focal mesangial pro-
liferative glomerulonephritis in the rat caused
by Habu snake venom: A morphologic study.
Am J Pathol 1977;87:511–524.
66 Cattell V, Mehotra A: Focal mesangial prolifer-
ative glomerulonephritis in the rat caused by
Habu venom: The effect of antiplatelet agents.
Br J Exp Pathol 1980;61:310–314.
67 Nakao H, Hiraiwa N, Yoshiki A, Ike F, Kusa-
kabe M: Tenascin-C promotes healing of
Habu-snake venom-induced glomerulonephri-
tis: Studies in knockout congenic mice and in
culture. Am J Pathol 1998;152:1237–1245.
68 Kashgarian M: Lupus nephritis: Lessons from
the path lab. Kidney Int 1994;45:928–938.
69 Theofilopoulos AN, Dixon FJ: Etiopathogene-
sis of murine SLE. Immunol Rev 1991;55:179–
216.
70 Diaz Gallo C, Jevnikar AM, Brennan DC, Flor-
quin S, Pacheco-Silva A, Kelley VR: Autoreac-
tive kidney-infiltrating T-cell clones in murine
lupus nephritis. Kidney Int 1992;42:851–859.
71 Mohan C, Datta SK: Lupus: Key pathogenic
mechanisms and contributing factors. Clin Im-
munol Immunopathol 1995;77:209–220.
72 Wakeland EK, Morel L, Mohan C, Yui M:
Genetic dissection of lupus nephritis in murine
models of SLE. J Clin Immunol 1997;17:272–
281.
73 Clynes R, Dumitru C, Ravetch JV: Uncoupling
of immune complex formation and kidney
damage in autoimmune glomerulonephritis.
Science 1998;279:1052–1054.
74 Haas C, Ryffel B, Le Hir M: IFN-gamma recep-
tor deletion prevents autoantibody production
and glomerulonephritis in lupus-prone (NZB
! NZW)F1 mice. J Immunol 1998;160:3713–
3718.
75 Schwarting A, Wada T, Kinoshita K, Tesch G,
Kelley VR: IFN-gamma receptor signaling is
essential for the initiation, acceleration, and
destruction of autoimmune kidney disease in
MRL-Fas(lpr) mice. J Immunol 1998;161:494–
503.
76 Lloyd CM, Gonzalo JA, Salant DJ, Just J,
Gutierrez-Ramos JC: Intercellular adhesion
molecule-1 deficiency prolongs survival and
protects against the development of pulmonary
inflammation during murine lupus. J Clin In-
vest 1997;100:963–971.
77 Baldwin DS: Chronic glomerulonephritis:
Nonimmunologic mechanisms of progressive
glomerular damage. Kidney Int 1982;21:109–
120.
78 Neuringer JR, Brenner BM: Hemodynamic
theory of progressive renal disease: A 10-year
update in brief review. Am J Kidney Dis 1992;
22:98–104.
79 Striker GE, He CJ, Liu RH, Yang DCW, Za-
lups RK, Esposito C, Striker LJ: Pathogenesis
of nonimmune glomerulosclerosis: Studies in
animals and potential applications to humans.
Lab Invest 1995;73:596–605.
80 Kriz W, Elger M, Nagata M, Kretzler M, Uiker
S, Koeppen-Hageman I, Tenschert S, Lemley
KV: The role of podocytes in the development
of glomerular sclerosis. Kidney Int 1994;
45(suppl):64–72.
81 Doi T, Striker LJ, Gibson CC, Agodoa LY,
Brinster RL, Striker GE: Glomerular lesions in
mice transgenic for growth hormone and insu-
linlike growth factor-I. I. Relationship between
increased glomerular size and mesangial sclero-
sis. Am J Pathol 1990;137:541–552.
82 Doi T, Striker LJ, Kimata K, Peten EP, Ya-
mada Y, Striker GE: Glomerulosclerosis in
mice transgenic for growth hormone: Increased
mesangial extracellular matrix is correlated
with kidney mRNA levels. J Exp Med 1991;
173:1287–1290.
83 Wanke R, Hermanns W, Folger S, Wolf E,
Brem G: Accelerated growth and visceral le-
sions in transgenic mice expressing foreign
genes of the growth hormone family: An over-
view. Pediatr Nephrol 1991;5:513–521.
84 Brem G, Wanke R, Wolf E, Buchmüller T,
Müller M, Brenig B, Hermanns W: Multiple
consequences of human growth hormone ex-
pression in transgenic mice. Mol Biol Med
1989;6:531–547.
85 Weiher H, Noda T, Gray DA, Sharpe AH, Jae-
nisch R: Transgenic mouse model of kidney
disease: Insertional inactivation of ubiquitous-
ly expressed gene leads to nephrotic syndrome.
Cell 1990;62:425–434.
D
ow
nl
oa
de
d 
by
: 
UB
 d
er
 L
M
U 
M
ün
ch
en
   
   
   
   
   
   
   
   
   
   
   
   
 
12
9.
18
7.
25
4.
47
 - 
8/
12
/2
01
3 
12
:0
2:
20
 P
M
192 Exp Nephrol 2000;8:181–193 Anders/Schlöndorff
86 MacKay K, Striker LJ, Pinkert CA, Brinster
RL, Striker GE: Glomerulosclerosis and renal
cysts in mice transgenic for the early region of
SV40. Kidney Int 1987;32:827–837.
87 Kollias G, Evans DJ, Ritter M, Beech J, Mor-
ris R, Grosveld F: Ectopic expression of Thy-
1 in the kidneys of transgenic mice induces
functional and proliferative abnormalities.
Cell 1987;51:21–31.
88 Zalups RK: The Os/+ mouse: A genetic ani-
mal model of reduced renal mass. Am J Phys-
iol 1993;264:F53–F60.
89 He C, Esposito C, Phillips C, Zalups RK,
Henderson DA, Striker GE, Striker LJ: Disso-
ciation of glomerular hypertrophy, cell prolif-
eration, and glomerulosclerosis in mouse
strains heterozygous for a mutation (Os)
which induces a 50% reduction in nephron
number. J Clin Invest 1996;97:1242–1249.
90 Lenz O, Zheng F, Vilar J, Doublier S, Lupia
E, Schwedler S, Striker LJ, Striker GE: The
inheritance of glomerulosclerosis in mice is
controlled by multiple quantitative loci.
Nephrol Dial Transplant 1998;13:3074–
3078.
91 Remuzzi G, Bertani T: Pathophysiology of
progressive nephropathies. N Engl J Med
1998;339:1448–1456.
92 Bruijn JA, Hogendorn PCW, Corver WE, van
Elven EH, Hodemaker PJ, Fleuren GJ: Renal
pathology and characterization of glomerular
sclerosis in murine chronic graft-versus-host
disease. Nephrol Dial Transplant 1987;2:
422–427.
93 Han JS, Doi K: Morphometric study on the
renal glomeruli of streptozotocin (SZ)-in-
duced diabetic APA hamsters. Histol Histo-
pathol 1992;7:549–554.
94 Honoi K, Doi K, Mitsuoka T: Histopathology
of streptozotocin-induced diabetic DBA/2N
and CD-1 mice. Lab Anim 1986;20:298–
303.
95 Steffens MW, Maurer SM: Diabetic glomeru-
lopathy in man and experimental models. Int
Rev Exp Pathol 1984;26:147–175.
96 Kume E, Doi C, Itagaki SI, Nagashima Y, Doi
K: Glomerular lesions in unilateral nephrec-
tomized and diabetic (UN-D) mice. J Vet
Med Sci 1992;54:1085–1090.
97 Velasquez MT, Kimmel PL, Michaelis OE:
Animal models of spontaneous diabetic kid-
ney disease. FASEB J 1990;4:2850–2859.
98 Doi T, Hattori M, Agodoa LY, Sato T, Yoshi-
da H, Striker LJ, Striker GE: Glomerular
lesions in nonobese diabetic mouse: Before
and after the onset of hyperglycemia. Lab
Invest 1990;63:204–212.
99 Yang CW, Hattori M, Vlassara H, He CJ,
Carome MA, Yamato E, Elliot S, Striker GE,
Striker LJ: Overexpression of transforming
growth factor-beta 1 mRNA in associated
with up-regulation of glomerular tenascin and
laminin gene expression in nonobese diabetic
mice. J Am Soc Nephrol 1995;5:1610–1617.
100 Gartner K: Glomerular hyperfiltration during
the onset of diabetes mellitus in two strains of
diabetic mice (C57BL/6J db/db and C57BL/
KsJ db/db). Diabetologia 1978;15:59–63.
101 Cohen MP, Clements RS, Hud E, Cohen JA,
Ziyadeh FN: Evolution of renal function ab-
normalities in the db/db mouse that parallels
the development of human diabetic nephrop-
athy. Exp Nephrol 1996;4:166–171.
102 Lubec B, Rokitansky A, Hayde M, Aufricht
C, Wagner U, Mallinger WR, Hoger H, Lubec
G: Thiaproline reduces glomerular basement
membrane thickness and collagen accumula-
tion in the db/db mouse. Nephron 1994;66:
333–336.
103 Wehner H, Hohn D, Faix-Schade U, Huber
H, Walzer P: Glomerular changes in mice
with spontaneous hereditary diabetes. Lab In-
vest 1972;27:331–340.
104 Melez KA, Harrison LC, Gilliam JN, Stein-
berg AD: Diabetes is associated with autoim-
munity in the New Zealand obese (NZO)
mouse. Diabetes 1980;29:835–840.
105 Sumida T, Furukawa M, Sakamoto A, et al:
Prevention of insulitis and diabetes in beta-
2-microglobulin-deficient non-obese diabetic
mice. Int Immunol 1994;6:1445–1449.
106 Kelly CJ, Neilson EG: Tubulointerstitial dis-
ease; in Brenner BM (ed): The Kidney. Phila-
delphia, Saunders, 1996, pp 1655–1680.
107 Wilson CB: Immune models of tubulointer-
stitial injury; in Neilson EG, Couser WC
(eds): Immunologic Renal Diseases. New
York, Lippincott-Raven, 1997, pp 775–804.
108 Neilson EG, McCafferty E, Feldman A, Clay-
man MD, Zakheim B, Korngold R: Sponta-
neous interstitial nephritis in kdkd mice. I.
An experimental model of autoimmune renal
disease. J Immunol 1984;133:2560–2565.
109 Kelly CJ, Korngold R, Mann R, Clayman M,
Haverty T, Neilson EG: Spontaneous intersti-
tial nephritis in kdkd mice. II. Characteriza-
tion of a tubular antigen-specific, H-2K-re-
stricted Lyt-2+ effector T cell that mediates
destructive tubulointerstitial injury. J Immu-
nol 1986;136:526–531.
110 Rudofsky UH, Dilwith RL, Tung KSK: Sus-
ceptibility differences in inbred mice to in-
duction of autoimmune renal tubulointersti-
tial lesions. Lab Invest 1980;43:463–470.
111 Neilson EG, McCafferty E, Mann R, Mi-
chaud L, Clayman M: Murine interstitial ne-
phritis. III. The selection of phenotypic (Lyt
and L3T4) and idiotypic (RE-Id) T cell pref-
erences by genes in IgH-1 and H-2K charac-
terizes the cell-mediated potential for dis-
ease expression: Susceptible mice provide a
unique effector T cell repertoire in response
to tubular antigen. J Immunol 1985;134:
2375–2382.
112 Rubin-Kelley VE, Jevnikar AM: Antigen pre-
sentation by renal tubular epithelial cells. J
Am Soc Nephrol 1991;2:13–16.
113 Zagheim B, McCafferty E, Phillips SM, Clay-
man M, Neilson EG: Murine interstitial ne-
phritis. II. The adoptive transfer of disease
with immune T lymphocytes produces a phe-
notypically complex interstitial lesion. J Im-
munol 1984;133:234–239.
114 Harris KPG, Klahr S, Schreiner G: Obstruc-
tive nephropathy: From mechanical distur-
bance to immune activation? Exp Nephrol
1993;1:198–204.
115 Steinhardt GF, Ramon G, Salinas-Madrigal
L: Glomerulosclerosis in obstructive uropa-
thy. J Urol 1988;140:1316–1318.
116 Fern RJ, Yesko CM, Thornhill BA, Kim HS,
Smithies O, Chevalier RL: Reduced angioten-
sinogen expression attenuates renal intersti-
tial fibrosis in obstructive nephropathy in
mice. J Clin Invest 1999;103:39–46.
117 Lee BJ, Boring L, Hwang O, Tomaszewski JE,
Charo I, Danoff TM: Obstructive nephropa-
thy in CCR2-deficient mice (abstract). J Am
Soc Nephrol 1998;9:2455.
118 Miao J, Roberts ISD, Schiffer M, Bottinger
EP: Unilateral ureter obstruction (UUO) in
mice with deletion of one allele of TGF-beta
(abstract 2184). J Am Soc Nephrol 1998;9:
427.
119 Yamasaki Y, Danoff T, Iwano M, Takahashi
K, Neilson E: B7 on tubular epithelial cells
accelerate local inflammation and may trigger
autoimmune reaction (abstract 2406). J Am
Soc Nephrol 1998;9:470.
120 Ma J, Nishimura H, Fogo A, Kon V, Inagami
T, Ichikawa I: Accelerated fibrosis and colla-
gen deposition develop in the renal intersti-
tium of angiotensin type 2 receptor null mu-
tant mice during ureteral obstruction. Kidney
Int 1998;53:937–944.
121 Thadhani R, Pascual M, Bonventre JV: Acute
renal failure. N Engl J Med 1996;334:1448–
1460.
122 Ling H, Edelstein C, Gengaro P, Meng X,
Lucia S, Knotek M, Wangsiripaisan A, Shi Y,
Schrier R: Attenuation of renal ischemia-
reperfusion injury in inducible nitric oxide
synthase knockout mice. Am J Physiol 1999;
277:F383–F390.
123 Nogae S, Miyazaki M, Kobayashi N, Saito T,
Abe K, Saito H, Nakane PK, Nakanishi Y,
Koji T: Induction of apoptosis in ischemia-
reperfusion model of mouse kidney: Possible
involvement of Fas. J Am Soc Nephrol 1998;
9:620–631.
124 Ouellette AJ, Malt RA, Sukhatme VP, Bon-
ventre JV: Expression of two ‘immediate ear-
ly’ genes, Egr-1 and c-fos, in response to renal
ischemia and during compensatory renal hy-
pertrophy in mice. J Clin Invest 1990;85:
766–771.
125 Haq M, Norman J, Saba SR, Ramirez G,
Rabb H: Role of Il-1 in renal ischemic reper-
fusion injury. J Am Soc Nephrol 1998;9:614–
619.
126 Kelly KJ, Williams WW, Colvin RB, Meehan
SM, Springer TA, Gutierrez-Ramos JC, Bon-
ventre JV: Intercellular adhesion molecule-1-
deficient mice are protected against ischemic
renal injury. J Clin Invest 1996;97:1056–
1063.
127 Rabb H, Ramirez G, Saba SR, Reynolds D,
Xu J, Flavell R, Antonia S: Renal ischemic-
reperfusion injury in L-selectin-deficient
mice. Am J Physiol 1996;271:F408–F413.
128 Zager RA, Conrad S, Lochhead K, Sweeney
EA, Igarashi Y, Burkhart KM: Altered sphin-
gomyelinase and ceramide expression in the
setting of ischmic and nephrotoxic acute renal
failure. Kidney Int 1998;53:573–582.
D
ow
nl
oa
de
d 
by
: 
UB
 d
er
 L
M
U 
M
ün
ch
en
   
   
   
   
   
   
   
   
   
   
   
   
 
12
9.
18
7.
25
4.
47
 - 
8/
12
/2
01
3 
12
:0
2:
20
 P
M
Murine Models of Renal Disease Exp Nephrol 2000;8:181–193 193
129 Parchure M, Ambaye RY, Lalitha VS, Gok-
hale SV: Acute toxicity of folic acid in mice.
Exprientia 1985;15:72–73.
130 Calvet JP, Chadwick LJ: Primary and second-
ary genetic responses after folic acid-induced
acute renal injury in the mouse. J Am Soc
Nephrol 1994;5:1324–1332.
131 Cowley BD, Chadwick LJ, Grantham JJ, Cal-
vet JP: Sequential protooncogene expression
in regenerating kidney following acute renal
injury. J Biol Chem 1989;15:8389–8393.
132 Kujubu DA: Differences in ‘primary re-
sponse’ gene expression in renal compensato-
ry hypertrophy and hyperplasia. Am J Kidney
Dis 1991;17:641–643.
133 Zager RA: Rhabdomyolysis and myohemo-
globinuric acute renal failure. Kidney Int
1996;49:314–326.
134 Ponraj D, Gopalakrishnakone P: Establish-
ment of an animal model for myoglobinuria
by use of a myotoxin from Pseudechis austra-
lis (king brown snake) venom in mice. Lab
Anim Sci 1996;46:393–398.
135 Ponraj D, Gopalakrishnakone P: Renal le-
sions in rhabdomyolysis caused by Pseudechis
australis snake myotoxin. Kidney Int 1997;
51:1956–1969.
136 Hata A, Tsunoo H, Nakajima H, Sgintaku K,
Kimura M: Acute cadmium intoxication in
inbred mice: A study on strain differences.
Chem Biol Interact 1980;32:29–39.
137 Dorian C, Gattone VH, Klassen CD: Discrep-
ancy between the nephrotoxic potencies
of cadmium-metallothionein and cadmium
chloride and the renal concentration of cad-
mium in the proximal convoluted tubules.
Toxicol Appl Pharmacol 1995;130:161–168.
138 Maitani T, Cuppage FE, Klaassen CD: Neph-
rotoxicity of intravenously injected cad-
mium-metallothionein: Critical concentra-
tion and tolerance. Fundam Appl Toxicol
1988;10:98–108.
139 Diamond GL, Zalups RK: Understanding re-
nal toxicity of heavy metal. Toxicol Pathol
1998;26:92–103.
140 Moszczynski P: Mercury compounds and the
immune system: A review. Int J Occup Med
Environ Health 1997;10:247–258.
141 Nielsen JB, Andersen HR, Andersen O,
Starklint H: Dose and time relation in Hg
(++)-induced tubular necrosis and regenera-
tion. Environ Health Perspect 1994;102
(suppl 3):317–320.
142 Tanaka T, Naganuma A, Imura N: Role of
gamma-glutamyltranspeptidase in renal up-
take and toxicity of inorganic mercury in
mice. Toxicology 1990;60:187–198.
143 Gabizon D, Goren E, Shaked U, Averbukh
Z, Rosenmann E, Modai D: Induction of
chronic renal failure in the mouse: A new
model. Nephron 1985;40:349–352.
144 Gibb IA, Hamilton DN: An experimental
model of chronic renal failure in mice. Clin
Immunol Immunopathol 1985;35:276–284.
145 Kren S, Hostetter TH: The course of the rem-
nant kidney model in mice. Kidney Int 1999;
56:333–337.
146 Gagnon RF, Gallimore B: Characterization
of chronic uremia. Urol Res 1988;16:119–
126.
147 Banchaabouchi MA, Marescau B, D’Hooge
R, Van Marck E, Van Daele A, Levillain O,
De Deyn PP: Biochemical and histopatholog-
ical changes in nephrectomized mice. Metab-
olism 1998;47:355–361.
148 Gagnon RF, Ansari M: Development and
progression of uremic changes in the mouse
with surgically induced renal failure. Neph-
ron 1990;54:70–76.
149 Gagnon RF, Gold J, Gerstein W: A mouse
model of delayed-type hypersensitivity skin
changes in chronic renal failure. Uremia In-
vest 1984;8:121–125.
150 Brox AG, Zhang F, Guyda H, Gagnon RF:
Subtherapeutic erythropoietin and insulin-
like growth factor-1 correct the anemia of
chronic renal failure in the mouse. Kidney Int
1996;50:937–943.
D
ow
nl
oa
de
d 
by
: 
UB
 d
er
 L
M
U 
M
ün
ch
en
   
   
   
   
   
   
   
   
   
   
   
   
 
12
9.
18
7.
25
4.
47
 - 
8/
12
/2
01
3 
12
:0
2:
20
 P
M
